Portal hypertension
Drug research and approvals for portal hypertension: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 82 studies of portal hypertension are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 82
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated CirrhosisNCT07920744 · Not reported · Fifth Affiliated Hospital, Sun Yat-Sen University · starts Oct 28, 2026
- Treatment Outcomes and Predictors After Endovascular Intervention for Portal Hypertension-Related Gastrointestinal…NCT07918378 · Not reported · University Medical Center Ho Chi Minh City (UMC) · starts Oct 1, 2026
- Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLDNCT07877272 · Not reported · University Hospital Muenster · starts Oct 5, 2026
- Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic…NCT07847710 · Phase 2 · The First Affiliated Hospital with Nanjing Medical University · starts Sep 30, 2026
- Coil-Assisted Small-Diameter Covered-Stent Shunt Reduction for Refractory Hepatic Encephalopathy After TIPSNCT07799948 · Not applicable · Air Force Military Medical University, China · starts Sep 1, 2026
- A Prospective, Multicenter, Randomized Controlled Trial Investigating the Impact of Fasting Duration on Postoperative…NCT07774143 · Not applicable · The First Affiliated Hospital of Zhengzhou University · starts Jun 20, 2026
- Austrian PBC RegistryNCT07598669 · Not reported · Medical University of Vienna · starts Mar 18, 2026
- 4D-Flow MRI Assessment of Portal Hypertension and TIPS Outcomes in CirrhosisNCT07554183 · Not applicable · Assistance Publique - Hôpitaux de Paris · starts Aug 25, 2026
- Apixaban-PK Trial: Preventing Portal Hypertension Complications in CirrhosisNCT07521332 · Phase 4 · Asian Institute Of Medical Sciences · starts Apr 1, 2026
Phase 3 5
- CarvedilolAdrenergic receptor beta antagonist
- SomatostatinSomatostatin receptor agonist
- PropranololBeta-1 adrenergic receptor antagonist
- TimololBeta-1 adrenergic receptor antagonist
- SimvastatinHMG-CoA reductase inhibitor
Phase 2 10
- AlverineSerotonin 1a (5-HT1a) receptor antagonist
- Avenciguat
- Sulfur hexafluorideDiagnostic agent
- SorafenibSerine/threonine-protein kinase RAF inhibitor
- SapropterinPhenylalanine-4-hydroxylase activator
- EmpagliflozinSodium/glucose cotransporter 2 inhibitor
- CobiprostoneChloride channel protein 2 activator
- BelapectinGalectin-3 inhibitor
- PerflubutaneDiagnostic
- Ncx 1000
How its trials ended
282 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 39 whose ending is known, 41% met their primary endpoint, 15% missed it and 44% stopped early.
- Completed, result not reported8831%
- Ongoing7828%
- Status unknown7727%
- Met its primary endpoint166%
- Stopped: other or unclear93%
- Missed its primary endpoint62%
- Stopped: enrollment or feasibility41%
- Stopped: sponsor or business decision31%
- Stopped: lack of efficacy1<1%
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Jan 10, 2000 | VapreotideTreatment of esophageal variceal hemorrhage patients with portal hypertension. | Debiovision, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA